News
MedPage Today on MSN1d
Wegovy Pill Under Review; FDA Lifts Obesity Trial Clinical Hold; SGLT2s and SurgeryThe FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...
2h
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Receiving a generic version of Ozempic or Wegovy from a compounding pharmacy is normally both easier to access and cheaper.
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
The US Food and Drug Administration (FDA) accepted Novo Nordisk’s New Drug Application (NDA) submission for an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback